Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging

Nuclear Medicine and Biology

Volumn 37, Issue 8, 2010, Pages 873-883

  Yang, Jianquan ^a   Guo, Haixun ^a   Miao, Yubin ^a,b,c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha melanocyte stimulating hormone hybrid peptide; Arg Gly Asp conjugated; Dual receptor targeting human melanoma imaging

Indexed keywords

CYCLIC(ARGINYLALANYLASPARTYLTYROSYLASPARTIC ACID)LYSINE(CYSTEINYLPHENYLALANYLARGININE)ALPHA MELANOCYTE STIMULATING HORMONE TC 99M; CYCLIC(ARGINYLGLYCYLASPARTYLTYROSYLASPARTIC ACID)LYSINE(CYSTEINYLPHENYLALANYLARGININE)ALPHA MELANOCYTE STIMULATING HORMONE SCRAMBLE TC 99M; CYCLIC(ARGINYLGLYCYLASPARTYLTYROSYLASPARTIC ACID)LYSINE(CYSTEINYLPHENYLALANYLARGININE)ALPHA MELANOCYTE STIMULATING HORMONE TC 99M; HYBRID PROTEIN; MELANOCORTIN 1 RECEPTOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER SCINTISCANNING; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; TUMOR XENOGRAFT;

EID: 78049486194     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.05.006     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Tatro J.B., Reichlin S. Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. Endocrinology 1987, 121:1900-1907.
3. Siegrist W., Solca F., Stutz S., Giuffre L., Carrel S., Girard J., et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 1989, 49:6352-6358.
4. 99mTechnetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res 2000, 60:5649-5658.
5. Miao Y., Whitener D., Feng W., Owen N.K., Chen J., Quinn T.P. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem 2003, 14:1177-1184.
6. 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide. Nucl Med Biol 2009, 36:267-276.
7. Giblin M.F., Wang N., Hoffman T.J., Jurisson S.S., Quinn T.P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA 1998, 95:12814-12818.
8. Froidevaux S., Calame-Christe M., Tanner H., Sumanovski L., Eberle A.N. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 2002, 43:1699-1706.
9. Froidevaux S., Calame-Christe M., Schuhmacher J., Tanner H., Saffrich R., Henze M., et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004, 45:116-123.
10. 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 2007, 48:73-80.
11. 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med 2008, 49:823-829.
12. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
13. 3 for angiogenesis. Science 1994, 264:569-571.
14. Petitclerc E., Strömblad S., von Schalscha T.L., Mitjans F., Piulats J., Montgomery A.M., et al. Integrin alpha(v)beta(3) promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999, 59:2724-2730.
15. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002, 2:91-100.
16. Cheresh D.A., Spiro R.C. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 1987, 262:17703-17711.
17. Cheresh D.A., Harper J.R. Arg-Gly-Asp recognition by a cell adhesion receptor requires its 130-kDa alpha subunit. J Biol Chem 1987, 262:1434-1437.
18. Albelda S.M., Mette S.A., Elder D.E., Stewart R., Damjanovich L., Herlyn M., et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res 1990, 50:6757-6764.
19. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., et al. Radiolabeled alpha(v)beta(3) integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999, 40:1061-1071.
20. Poethko T., Schottelius M., Thumshirn G., Hersel U., Herz M., Henriksen G., et al. Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J Nucl Med 2004, 45:892-902.
21. Li C., Wang W., Wu Q., Ke S., Houston J., Sevick-Muraca E., et al. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol 2006, 33:349-358.
22. 99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol 2006, 33:945-952.
23. 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys). Bioconjug Chem 2007, 18:530-537.
24. 111In-labelled DOTA-RGD peptides for imaging of alpha(v)beta(3) integrin expression. Eur J Nucl Med Mol Imaging 2008, 35:1507-1515.
25. 18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). Eur J Nucl Med Mol Imaging 2009, 36:1469-1474.
26. 64Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl Med Biol 2009, 36:277-285.
27. Yang J., Guo H., Gallazzi F., Padilla R.S., Berwick M., Miao Y. Evaluation of a novel RGD-conjugated alpha-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem 2009, 20:1634-1642.
28. 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46:1707-1718.
29. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 2002, 101:480-487.
30. Antunes P., Ginj M., Walter M.A., Chen J., Reubi J., Maecke H.R. Influence of different spacers on the biological profile of a DOTA-Somatostatin analogue. Bioconjug Chem 2007, 18:84-92.